ML339

CAT: 0804-HY-122197-01Size: 5 mgDry Ice: NoHazardous: No
CAT#:0804-HY-122197-01Size:5 mg
Selected
AVAILABILITY: InStock
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Product image 1
1 / 1
Description
ML339 is a selective CXCR6 antagonist with an IC50 of 140 nM. ML339 antagonizes β-arrestin recruitment and cAMP signaling pathway of human CXCR6 receptor induced by CXCL16, with IC50 of 0.3 μM and 1.4 μM, respectively. ML339 shows weaker activity against the recruitment of β-arrestin in mouse CXCR6 receptors, with an IC50 of 18 μM. ML339 has no inhibitory effect on CXCR5, CXCR4, CXCR6 and apelin receptor (APJ), with IC50 >79 μM. ML339 has the potential to promote the development of prostate cancer research[1][2].
CAS Number
[2579689-83-9]
UNSPSC
12352005
Target
Apelin Receptor (APJ) ; Arrestin; CXCR
Type
Reference compound
Related Pathways
GPCR/G Protein; Immunology/Inflammation
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/ml339.html
Purity
99.88
Solubility
DMSO : 75 mg/mL (ultrasonic)
Smiles
O=C(C1=CC(OC)=C(C(OC)=C1)OC)N[C@@H]2C[C@@H](CCC[C@H]3C2)N3CC(NC4=CC=CC=C4Cl)=O
Molecular Formula
C26H32ClN3O5
Molecular Weight
502.00
References & Citations
[1]Paul M Hershberger, et al. Probing the CXCR6/CXCL16 Axis: Targeting Prevention of Prostate Cancer Metastasis.|[2]Peddibhotla S, et al. Discovery of small molecule antagonists of chemokine receptor CXCR6 that arrest tumor growth in SK-HEP-1 mouse xenografts as a model of hepatocellular carcinoma. Bioorg Med Chem Lett. 2020 Feb 15;30 (4) :126899.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
CXCR6

Alternative Products

CatalogName
BUP03271-01ML339

Popular Products